The Rotherham NHS Foundation Trust Library & Knowledge Service
  • About Us
    • What we do
    • Can I join?
    • How to find us
    • A-Z of services
    • Book Group
    • Publications Repository
    • Contact us
    • Privacy Policy
    • Accessibility
  • My Speciality
  • Resources
  • Training
  • Request Search
  • Keep up to date
  • Knowledge Mobilisation
 
Picture

  • Boyd, KD (2011) Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiology, Biomarkers & Prevention 2011; 20: 8, 1703-1707
    ​​
  • Gascón, Pete et al. (2011a)  Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Critical Reviews in Oncology/Hematology 77 (2011) 184–197

  • Gascón, Pere et al (2011b) Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Critical Reviews in Oncology/Hematology 77 (2011) 198–200

  • Johnson DC et al. (2011) Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma Journal of Clinical Oncology 29:797-804.

  • Morgan GJ et al. (2011a) Cyclophosphamide, Thalidomide, and Dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation Blood. 2011; 118: 1231-1238

  • Morgan GJ et al.(2011b) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncology 2011; 12(8): 743-752. 

  • Tapper W et al. (2011) Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in Multiple Myeloma. In: Journal of Clinical Oncology 2011; 29(2) e37-e39

  • Whittle, R & Taylor PC (2011) Circulating B-cell activating factor level predicts clinical response of chronic graft-versus-host disease to extracorporeal photopheresis. Blood. 2011 Dec 8;118(24):6446-9

  • Wu, P et al. (2011) A gene expression based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clinical Cancer Research 2011; 17: 6347-6355

  • Yokoyama S et al. (2011)   A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480 (7375):99-103
Picture
Picture
2023
2022
2021
​2020
2019

2018
2017
2016
​2015
​
2014
2013
​2012
2011
2010
​2009

Repository home



Audiology
Cardiology
Dermatology
Endocrinology
​Gastroenterology
​
Intensive Care Medicine
​Haematology
HIV Medicine
Paediatrics
Patient Safety
​
Physiotherapy
Obstetrics & Gynaeocology
​Oncology
Respiratory Medicine
​Surgery
​
Wound Care​
 
Back to top
Contact us
Find us
A-Z of services



Privacy Policy 
Accessibility statement 
How can we improve?
Books
Journals
Health promotion resources



Request a search
Search the evidence
Speciality gateways
Request training
Help with Athens
Bulletins and alerts
All content © 2023 The Rotherham NHS Foundation Trust Library & Knowledge Service unless otherwise stated.